Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
Biohaven Ltd. (BHVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results • The US Food and Drug Administration (FDA) accepted new drug application resubmission for Vyglxia (troriluzole) in spinocerebeller ataxia (SCA), user fee goal date 1Q27. • Announc
How this was made
The 30-second read
Why it matters
The cash inflows and expanded geographic rights could materially improve Biohaven's balance sheet and pipeline commercialization prospects.
Market read
First‑report of large licensing deals and FDA resubmission acceptance likely moves Biohaven stock and may influence sector sentiment.
What to watch
Potential dilution from future equity raises if cash burn exceeds expectations; integration risk with foreign partners.
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
Third-quarter operating expenses and net loss declined year over year, while Biohaven secured significant partnership consideration and advanced several pipeline programs. Offsetting these developments, the company remains pre-revenue with a $129.3 million quarterly net loss, and opakalim new enrollment is subject to an FDA partial clinical hold pending additional nonclinical data.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30GAAP | $101.9M | – | decrease of $39.3 million |
| General and administrative expenses, three months ended September 30GAAP | $24.6M | – | decrease of $3.6 million |
| Total operating expenses, three months ended September 30GAAP | $126.4M | – | – |
| Loss from operations, three months ended September 30GAAP | −$126.4M | – | – |
| Other expense, net, three months ended September 30GAAP | $2.9M | – | decrease in expense of $0.9 million |
| Loss before benefit provision for income taxes, three months ended September 30GAAP | −$129.3M | – | – |
| Benefit provision for income taxes, three months ended September 30GAAP | −$64K | – | – |
| Net loss, three months ended September 30GAAP | $129.3M | – | – |
| Net loss per share, basic and diluted, three months ended September 30GAAP | $0.86 per share | – | – |
| Weighted average common shares outstanding, basic and diluted, three months ended September 30GAAP | 151,040,349 | – | – |
| Non-GAAP adjusted net loss, three months ended September 30non-GAAP | $110.7M | – | – |
| Non-GAAP adjusted net loss per share, basic and diluted, three months ended September 30non-GAAP | $0.73 per share | – | – |
| Non-cash share-based compensation expense, three months ended September 30GAAP | $12.1M | – | decrease of $1.9 million |
| Non-cash share-based compensation expense in general and administrative expenses, three months ended September 30GAAP | $6.6M | – | decrease of $1.0 million |
| Research and development expenses, nine months ended September 30GAAP | $306.5M | – | – |
| General and administrative expenses, nine months ended September 30GAAP | $75.26M | – | – |
| Total operating expenses, nine months ended September 30GAAP | $381.7M | – | – |
| Loss from operations, nine months ended September 30GAAP | −$381.7M | – | – |
| Other expense income, net, nine months ended September 30GAAP | −$14.78M | – | – |
| Loss before benefit provision for income taxes, nine months ended September 30GAAP | −$396.5M | – | – |
| Benefit provision for income taxes, nine months ended September 30GAAP | $599K | – | – |
| Net loss, nine months ended September 30GAAP | −$397.1M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30GAAP | $ (2.65) | – | – |
| Weighted average common shares outstanding, basic and diluted, nine months ended September 30GAAP | 149,776,602 | – | – |
| Non-GAAP adjusted net loss, nine months ended September 30non-GAAP | −$331.0M | – | – |
| Non-GAAP adjusted net loss per share, basic and diluted, nine months ended September 30non-GAAP | $ (2.21) | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $95.75M | – | – |
| Marketable securities, September 30, 2026GAAP | $65.37M | – | – |
| Total assets, September 30, 2026GAAP | $263.7M | – | – |
| Notes payable, September 30, 2026GAAP | $264.3M | – | – |
| Total liabilities, September 30, 2026GAAP | $361.9M | – | – |
| Total shareholders' deficit equity, September 30, 2026GAAP | −$98.25M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Expected Upcoming Milestones outlook
- NoteVyglxia (troriluzole) in SCA: FDA advisory committee meeting (date to be announced); user fee goal date in 1Q 2027.
- NoteSelective Kv7 Ion Channel Activator (Opakalim): Topline results for Phase 2/3 study expected in 2H 2026.
- NoteMyostatin-Activin Pathway Inhibitor (Taldefgrobep alfa): topline data expected in 2H 2027.
- NoteBHV-1300: Continue enrollment of patients in ongoing Phase 3 study in Graves' disease.
- NoteBHV-1400: Pivotal study initiation in IgAN targeted for 2H 2026.
- NoteBiohaven will receive an additional $350.0 million from SKBP upon the closing of the SKBP Agreement.
- NoteBiohaven will receive a $20 million milestone payment upon achievement of a milestone anticipated within a year of signing.
What drove it
- Research and development expenses decreased primarily because of decreases in direct program spend and preclinical spend following the strategic reprioritization of programs implemented in the fourth quarter of 2025.
- Ono licensing agreement provides up to $100 million in near-term payments, consisting of an $80 million upfront payment received to date and a $20 million milestone payment anticipated within a year, plus royalties of approximately 20 percent on net sales in the licensed territory.
- The SK Biopharmaceuticals agreement provides $400 million in cash consideration, consisting of $350 million payable at closing and $50 million payable one year after closing, plus eligibility for up to $150 million in development and regulatory milestone payments.
- The FDA accepted the Vyglxia new drug application resubmission for review and assigned a user fee goal date in the first quarter of 2027.
- BHV-1300 enrollment is ongoing in its Phase 3 Graves' disease study, and BHV-1400 pivotal-study initiation in IgAN is targeted for 2H 2026.
Concerns
- The FDA issued a partial clinical hold letter on September 4, 2026, pausing new patient enrollment for opakalim until additional clarifying nonclinical studies are completed.
- The significance of the nonclinical metabolite findings to humans is uncertain.
- Biohaven reported a GAAP net loss of $129.3 million for the three months ended September 30, 2026.
- Notes payable were $ 264,294 (Amounts in thousands), and total shareholders' deficit equity was $ (98,247) (Amounts in thousands) as of September 30, 2026.
- The SK Biopharmaceuticals transaction remains subject to remaining closing conditions.
What to watch
- Opakalim RISE 3 topline data, which remains on track for the second half of 2026.
- Completion of additional opakalim nonclinical studies and the status of the partial clinical hold on new enrollment.
- Closing of the SK Biopharmaceuticals agreement and receipt of the $350 million payment payable at closing.
- The FDA advisory committee meeting date and the first-quarter 2027 user fee goal date for Vyglxia in SCA.
- BHV-1400 pivotal-study initiation in IgAN targeted for 2H 2026.
- Taldefgrobep alfa Phase 2 monotherapy and combination-therapy topline data expected in 2H 2027.
Balance sheet and cash flow
- Cash, cash equivalents, marketable securities and restricted cash as of September 30, 2026, totaled approximately $164.0 million.
- On October 20, 2026, Biohaven received $80.0 million from Ono Pharmaceuticals.
- Notes payable were $ 264,294 (Amounts in thousands) as of September 30, 2026.
- Operating cash flow and free cash flow were not reported.
Analysis
Biohaven remained a clinical-stage company without reported revenue and recorded a GAAP net loss of $129.3 million, or $0.86 per share, for the three months ended September 30, 2026. The loss narrowed from $173.4 million, or $1.64 per share, in the prior-year period. Non-GAAP adjusted net loss was $110.7 million, or $0.73 per share, compared with $155.9 million, or $1.47 per share.
The improvement was driven by lower operating spending. R&D expense was $101.9 million, down $39.3 million, principally from reduced direct program and preclinical spend after the program reprioritization implemented in the fourth quarter of 2025. G&A expense was $24.6 million, down $3.6 million, primarily due to lower employee costs including share-based compensation. Other expense, net was $2.9 million, compared with $3.8 million.
The principal strategic development was the monetization of two pipeline platforms. Biohaven received $80.0 million from Ono Pharmaceuticals on October 20, 2026 and may receive up to $100 million in near-term payments under the regional MoDE portfolio license. The SK Biopharmaceuticals agreement provides for $400 million in cash consideration, including $350 million at closing, while SKBP will assume Kv7 program costs going forward. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $164.0 million as of September 30, 2026, before the reported Ono receipt and prospective SKBP closing payment.
Pipeline execution remains central to the period. The FDA accepted the Vyglxia resubmission in SCA, with a user fee goal date in the first quarter of 2027, while BHV-1300 is enrolling in Phase 3 and BHV-1400 pivotal-study initiation is targeted for 2H 2026. The key near-term risk is the partial clinical hold on new opakalim enrollment following metabolite findings in rodent testing. Biohaven stated that more than 600 randomized patients can continue dosing, RISE 3 is fully enrolled, and its topline data remains on track for the second half of 2026.
Management, verbatim
This quarter marked important progress in executing our strategy of building differentiated platforms and partnering them to create both near-term and long-term value.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven
Beyond these partnerships, we continue to advance a diverse and innovative pipeline.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven
Not in the filing
stated, not guessed- Total revenue and revenue growth were not reported.
- Segment revenue and segment profitability were not reported.
- Gross profit, gross margin, operating income, and operating margin were not reported.
- Operating cash flow, capital expenditures, free cash flow, dividends, and share repurchases were not reported.
- Financial revenue, gross-margin, operating-expense, or tax-rate guidance was not reported.
- Prior-quarter comparisons were not reported.
- A previous outlook section was not provided.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The 8‑K filing provides the first public details of Biohaven's recent licensing agreements and FDA resubmission status.
Ticker impact
Biohaven disclosed a $400 million cash license deal with SK Biopharmaceuticals and up to $100 million from Ono Pharmaceutical, plus FDA acceptance of a new drug application resubmission.
likely upside as the market prices in the large cash consideration and expanded market reach.
The disclosed cash amounts are material for a mid‑cap biotech and represent the first public disclosure of these agreements.
Market effects
Boosts confidence in biotech licensing models and may lift peer valuations in rare‑disease space.
Strengthens US‑Asia biotech collaboration narrative, especially for Japan and South Korea.
Highlights growing cross‑border biotech partnerships, relevant for global healthcare investors.
Counterpoint
If the partnerships delay product launches or face regulatory hurdles, the cash may not translate to near‑term earnings, limiting upside.
Key entities
- partnerSK Biopharmaceuticals Co., Ltd.
Recipient of exclusive global license to Biohaven's Kv7 ion channel platform.
- partnerOno Pharmaceutical Co., Ltd.
Exclusive licensee for Biohaven's MoDE IgG degrader portfolio in several Asian markets.
